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Menstrual bleeding patterns in adolescents using etonogestrel
(ENG) implant

Amit M. Deokar, Wendy Jackson and Hatim A. Omar*
Department of Pediatrics, Division of Adolescent
Medicine and Department of Obstetrics and Gynecology,
Kentucky Women’s Health, University of Kentucky,
Lexington, KY, USA

Abstract
Background: Etonogestrel (ENG) implant is an effective
method of contraception. The implant is designed to provide
contraceptive efficacy for 3 years with a relatively quick return
of fertility upon its removal. Menstrual irregularities are not
uncommon on long-acting progestins and can often be the
factor for discontinuation or removal. A retrospective chart
analysis was done on 58 patients who chose to be on the ENG
implant. Age ranged from 12 to 24 years. The cycle ranged
from 1 to 17 months. The mean length of use of the implant
was 10.9 months. Over the 20-month period, 13 ENG implants
were removed because of menstrual bleeding problems.
Method: We conducted a chart review of the adolescent
patients who received the ENG implant in our adolescent
clinic. An analysis was done based on symptoms experienced
by patients who were on the ENG implant and their management, which in some cases resulted in its removal.
Setting: The data is presented on adolescent and young adult
patients who receive their reproductive care in the Adolescent
Medicine Clinic at the University of Kentucky, Lexington,
KY, USA.
Conclusions: ENG implant when used correctly and as indicated is extremely effective in providing contraception for
up to 3 years. However, menstrual irregularities can be very
troublesome and often a reason for its removal. In our experience, 22.4% (13 out of the 58 subjects) had menstrual problems post-insertion that led to its removal. It is crucial for a
clinician to inform and be informed about such side effects.
Keywords: adolescents; contraceptives; depot medroxyprogesterone acetate; doxycycline; ethinyl estradiol; etonogestrel
(ENG); mifepristone; progesterone/progestin.
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Introduction
There are more than 20 million women worldwide who use
long-acting progesterone-only contraceptives (1, 2). These
are extremely effective contraceptives with a failure rate of
0.3%–1.0% annually (2). Etonogestrel (ENG) implant marketed as Implanon™ is a progestin-only subdermal contraceptive
implant that was first marketed in Indonesia in 1998 (3, 4).
Since then, more than 3 million implants have been dispensed
throughout the world. It was first approved in the US by the
Food and Drug Administration (FDA) in 2006 (3, 5). It consists
of a sterile non-biodegradable single rod implant (dimension:
4 cm×2 mm) that contains 68 mg of the biologically active
metabolite of Desogestrel called Etonogestrel (ENG) (1, 3–5).
There is a gradual decline in the hormone released from approximately 60–70 µg/day following a few weeks after its
insertion to approximately 25–30 µg by the end of 3 years (4,
6, 7). Some important features of the implant are as follows:
(i) mechanism of action of the ENG implant; (ii) one of the
most common reasons for its discontinuation, i.e., menstrual
irregularities; and (iii) data from the chart review of patients in
our clinic who experienced menstrual irregularities.
The contraceptive mechanisms of the ENG implant are as
follows (4, 6, 7): (a) suppression of luteinizing hormone surge
(although the follicle stimulating hormone is also suppressed,
but only partially); (b) increased viscosity of the cervical
mucus that impedes sperm penetration; and (c) alteration
(thinning) of the endometrium.
At present, clinicians are required to undergo training conducted by Organon (manufacturer) before they can insert the
Implanon™ in a patient. Within 1–2 weeks of removal of the
Implanon™, fertility is reversed (6, 8). There are some other
key clinical features of Implanon™ that a clinician needs to be
aware of and are listed below (4, 7, 9).
1. For a patient who seeks a long-acting progesterone
implant, the clinician must provide adequate pre- and
post-insertion counseling. This is very crucial because
menstrual abnormalities continue to be the most common
reason for discontinuation and removal of the implant.
Even though data might be inconclusive on progesterone
directly increasing the risk of thrombosis, women should
still be counseled to refrain from tobacco smoke.
2. Informed consent must be obtained before the insertion,
removal or replacement. It is of utmost importance for the
patient to know that Implanon™ does not prevent sexually
transmitted infections, and appropriate measures must be
taken to prevent such infections.
3. During its clinical trials, Implanon™ was not studied in
women who weighed more than 130% of their ideal body
weight. The serum concentration of ENG is inversely
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proportional to the body weight and the length of time for
which the implant was in place.
Over the course of multiple years, the ENG implant is
more cost-effective than combined oral contraceptives.
Unintended pregnancies in the first year of the Implanon™
use are estimated to be <0.05% (1 in 100 users).
As a result of drug interactions, plasma levels of ENG can
vary especially if the patient is on medications that induce
or inhibit the hepatic enzymes.
When compared to depot medroxyprogesterone acetate,
the effect of Implanon™ on bone mineral density (BMD) is
reassuring. In contrast, pregnancy and lactation have relatively worse effects on bone density. BMD usually returns
to baseline within a few years of stopping the long-acting
progesterone containing contraceptives.

maximum number days the patients retained their Implanon™
post-insertion varied from 26 days to 17 months before they
were electively discontinued and removed. Out of the 58
patients, 13 (22.4%) requested removal and discontinuation
of Implanon™ primarily because of menstrual irregularities.
The menstrual problems ranged from spotting to an overt
period. The duration of bleeding post-ENG implant was categorized into 1–7 days and continuous (more than 7 days and
multiple breakthrough bleeding episodes). The management
of such bleeding patterns included use of combination contraceptive pills to removal of the implant. Based on our data,
this is one of the highest percentages of patients opting for its
discontinuation and removal.

Management of menstrual irregularities
Side effects
Contraceptives containing long-acting progesterone are invaluable in preventing teen pregnancy. Implanon™ is a good
example of one such contraceptive. All hormonal contraceptives have a certain side-effect profile, including the ENG
implant. This article focuses on menstrual irregularities and
problems associated with its use and how they can influence
patients desire to opt for its discontinuation/removal.
There are varying patterns of menstrual abnormalities that
are possible with Implanon™ use. These include amenorrhea,
prolonged and heavy bleeding, irregular bleeding, spotting,
and an unpredictable bleeding pattern, etc. (1, 3, 4, 7). The
most frequent reason reported by women is unpredictable
and irregular vaginal bleeding. In Implanon™ users, the
bleeding pattern is most likely to vary in the first 3 months
after insertion (6). This can lead to frustration and poor quality of life. These issues can cause anxiety and discontent in
the teenager ’s mind. It is advisable to keep a menstrual diary
that will help the clinician to manage the menstrual problems
effectively.
There are several reasons cited that play a role in the bleeding irregularities in progesterone users. These include altered
endometrial matrix metalloproteinase (MMP), vascular fragility, irregular endometrial blood vessels, decreased glandular
and stromal support, and decreased integrity of the epithelium (1, 10). According to Weisberg et al. (1) and Monsour
et al. (11), a review of 11 clinical trials involving Implanon™
(n=923) revealed that 11.3% of the users discontinued it
because of prolonged and frequent menstrual bleeding (1, 11).
Differences in culture, personal and social factors, and tolerance to bleeding irregularities can largely affect one’s decision to discontinue with Implanon™ (6).

Chart review
From February 2008 to October 2009, a total number of 58
patients received Implanon™, which was placed by certified
and trained clinicians in the Division of Adolescent Medicine, University of Kentucky, Lexington, KY, USA. The
age range of the patients was between 12 and 24 years. The

A variety of treatment options are available for menstrual
irregularities associated with Implanon™ use. Some are more
effective than others and thus need to be patient-specific (1,
7). It is crucial to not use any of these recommendations in
undiagnosed vaginal bleeding.
• Doxycycline 100 mg twice daily for 5 days. The inhibition
of MMP mediated degeneration of the endometrial matrix
is believed to be the mechanism of its action.
• Mifepristone (25 mg) twice for 1 day followed by ethinyl
estradiol (EE) 10 µg twice a day for 4 days. Such a regimen depends on the availability of mifepristone and that
there are no contraindications for its use along with EE.
Mifepristone works by stabilizing the endometrium by its
rapid repair action.
• Combination oral contraceptives. The dose and duration
is a matter of the clinician’s preference and patient’s
tolerability.
• Non-streroidal anti-inflammatory drugs (NSAIDs). An example is high dose of ibuprofen (800 mg three times a day)
or mefenamic acid (500 mg three times a day) for 5 days.
NSAIDs act by blocking the prostaglandin synthesis.
Platelet aggregation and endometrial vasoconstriction can
also play a crucial role.

Conclusion
Long-acting progesterone contraceptives are extremely
effective in preventing teen pregnancies. Some contraceptives such as Implanon™ also allow relatively quick return
of fertility. They can be very cost-effective when used over
multiple years. However, menstrual irregularities and problems are some of the major reasons for its discontinuation
and removal. Therefore, it is very important for the clinician
to provide the patient with adequate pre-, post-insertion, and
pre-removal counseling so that an educated decision can be
facilitated.
There are patient specific recommendations to manage
the bleeding irregularities and include a choice of doxycycline, EE, mifepristone, combination oral contraceptives,
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and NSAIDs. Patients who discontinue Implanon™ should be
given an alternate contraceptive recommendation to prevent
an unintended pregnancy.
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